vs

Side-by-side financial comparison of Apollo Commercial Real Estate Finance, Inc. (ARI) and PROCEPT BioRobotics Corp (PRCT). Click either name above to swap in a different company.

PROCEPT BioRobotics Corp is the larger business by last-quarter revenue ($83.1M vs $73.3M, roughly 1.1× Apollo Commercial Real Estate Finance, Inc.). Apollo Commercial Real Estate Finance, Inc. runs the higher net margin — 39.9% vs -38.1%, a 77.9% gap on every dollar of revenue. On growth, PROCEPT BioRobotics Corp posted the faster year-over-year revenue change (20.2% vs 4.0%). Over the past eight quarters, PROCEPT BioRobotics Corp's revenue compounded faster (24.8% CAGR vs -4.6%).

Apollo Commercial Real Estate Finance, Inc. is a real estate investment trust that originates, acquires and manages commercial real estate debt assets including mortgages, mezzanine loans and mortgage-backed securities, primarily operating in the U.S. market to deliver consistent risk-adjusted returns.

PROCEPT BioRobotics Corp is a medical tech firm developing and commercializing robotic surgical solutions for urological care. Its flagship AquaBeam system provides image-guided minimally invasive therapy for benign prostatic hyperplasia, serving providers and patients across North America, Europe and global markets.

ARI vs PRCT — Head-to-Head

Bigger by revenue
PRCT
PRCT
1.1× larger
PRCT
$83.1M
$73.3M
ARI
Growing faster (revenue YoY)
PRCT
PRCT
+16.2% gap
PRCT
20.2%
4.0%
ARI
Higher net margin
ARI
ARI
77.9% more per $
ARI
39.9%
-38.1%
PRCT
Faster 2-yr revenue CAGR
PRCT
PRCT
Annualised
PRCT
24.8%
-4.6%
ARI

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
ARI
ARI
PRCT
PRCT
Revenue
$73.3M
$83.1M
Net Profit
$29.2M
$-31.6M
Gross Margin
64.9%
Operating Margin
39.7%
-4.1%
Net Margin
39.9%
-38.1%
Revenue YoY
4.0%
20.2%
Net Profit YoY
-28.2%
-27.9%
EPS (diluted)
$0.19
$-0.56

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ARI
ARI
PRCT
PRCT
Q1 26
$83.1M
Q4 25
$73.3M
$76.4M
Q3 25
$61.6M
$83.3M
Q2 25
$70.9M
$79.2M
Q1 25
$65.8M
$69.2M
Q4 24
$70.5M
$68.2M
Q3 24
$71.6M
$58.4M
Q2 24
$81.1M
$53.4M
Net Profit
ARI
ARI
PRCT
PRCT
Q1 26
$-31.6M
Q4 25
$29.2M
$-29.8M
Q3 25
$50.8M
$-21.4M
Q2 25
$20.7M
$-19.6M
Q1 25
$26.0M
$-24.7M
Q4 24
$40.7M
$-18.9M
Q3 24
$-91.5M
$-21.0M
Q2 24
$35.8M
$-25.6M
Gross Margin
ARI
ARI
PRCT
PRCT
Q1 26
64.9%
Q4 25
60.6%
Q3 25
64.8%
Q2 25
65.4%
Q1 25
63.9%
Q4 24
64.0%
Q3 24
63.2%
Q2 24
59.0%
Operating Margin
ARI
ARI
PRCT
PRCT
Q1 26
-4.1%
Q4 25
39.7%
-40.6%
Q3 25
82.8%
-27.8%
Q2 25
29.4%
-28.0%
Q1 25
39.7%
-39.7%
Q4 24
57.9%
-28.9%
Q3 24
-127.8%
-38.4%
Q2 24
44.2%
-50.3%
Net Margin
ARI
ARI
PRCT
PRCT
Q1 26
-38.1%
Q4 25
39.9%
-39.1%
Q3 25
82.4%
-25.7%
Q2 25
29.3%
-24.7%
Q1 25
39.5%
-35.8%
Q4 24
57.7%
-27.6%
Q3 24
-127.9%
-35.9%
Q2 24
44.1%
-48.0%
EPS (diluted)
ARI
ARI
PRCT
PRCT
Q1 26
$-0.56
Q4 25
$0.19
$-0.54
Q3 25
$0.34
$-0.38
Q2 25
$0.12
$-0.35
Q1 25
$0.16
$-0.45
Q4 24
$0.25
$-0.34
Q3 24
$-0.69
$-0.40
Q2 24
$0.23
$-0.50

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ARI
ARI
PRCT
PRCT
Cash + ST InvestmentsLiquidity on hand
$139.8M
$245.6M
Total DebtLower is stronger
$51.7M
Stockholders' EquityBook value
$1.9B
$347.7M
Total Assets
$9.9B
$487.1M
Debt / EquityLower = less leverage
0.15×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ARI
ARI
PRCT
PRCT
Q1 26
$245.6M
Q4 25
$139.8M
$286.5M
Q3 25
$245.9M
$294.3M
Q2 25
$177.6M
$302.7M
Q1 25
$166.4M
$316.2M
Q4 24
$317.4M
$333.7M
Q3 24
$194.3M
$196.8M
Q2 24
$174.7M
$214.1M
Total Debt
ARI
ARI
PRCT
PRCT
Q1 26
$51.7M
Q4 25
$51.6M
Q3 25
$51.6M
Q2 25
$51.5M
Q1 25
$51.5M
Q4 24
$51.5M
Q3 24
$51.4M
Q2 24
$51.4M
Stockholders' Equity
ARI
ARI
PRCT
PRCT
Q1 26
$347.7M
Q4 25
$1.9B
$365.9M
Q3 25
$1.9B
$380.3M
Q2 25
$1.8B
$385.8M
Q1 25
$1.9B
$389.2M
Q4 24
$1.9B
$402.2M
Q3 24
$1.9B
$241.2M
Q2 24
$2.0B
$251.8M
Total Assets
ARI
ARI
PRCT
PRCT
Q1 26
$487.1M
Q4 25
$9.9B
$508.1M
Q3 25
$9.5B
$511.5M
Q2 25
$9.8B
$513.1M
Q1 25
$8.8B
$519.4M
Q4 24
$8.4B
$534.0M
Q3 24
$9.1B
$374.1M
Q2 24
$9.3B
$374.4M
Debt / Equity
ARI
ARI
PRCT
PRCT
Q1 26
0.15×
Q4 25
0.14×
Q3 25
0.14×
Q2 25
0.13×
Q1 25
0.13×
Q4 24
0.13×
Q3 24
0.21×
Q2 24
0.20×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ARI
ARI
PRCT
PRCT
Operating Cash FlowLast quarter
$142.5M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
4.88×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ARI
ARI
PRCT
PRCT
Q1 26
Q4 25
$142.5M
$-10.3M
Q3 25
$31.7M
$-6.6M
Q2 25
$63.2M
$-15.0M
Q1 25
$39.3M
$-17.0M
Q4 24
$200.3M
$-32.4M
Q3 24
$47.2M
$-18.8M
Q2 24
$50.2M
$-15.7M
Free Cash Flow
ARI
ARI
PRCT
PRCT
Q1 26
Q4 25
$-12.2M
Q3 25
$-9.5M
Q2 25
$-17.8M
Q1 25
$-18.8M
Q4 24
$-33.6M
Q3 24
$-19.0M
Q2 24
$-16.8M
FCF Margin
ARI
ARI
PRCT
PRCT
Q1 26
Q4 25
-15.9%
Q3 25
-11.4%
Q2 25
-22.5%
Q1 25
-27.2%
Q4 24
-49.2%
Q3 24
-32.6%
Q2 24
-31.4%
Capex Intensity
ARI
ARI
PRCT
PRCT
Q1 26
Q4 25
2.4%
Q3 25
3.4%
Q2 25
3.5%
Q1 25
2.7%
Q4 24
1.7%
Q3 24
0.4%
Q2 24
2.0%
Cash Conversion
ARI
ARI
PRCT
PRCT
Q1 26
Q4 25
4.88×
Q3 25
0.62×
Q2 25
3.05×
Q1 25
1.51×
Q4 24
4.93×
Q3 24
Q2 24
1.40×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ARI
ARI

Segment breakdown not available.

PRCT
PRCT

Handpieces and other consumables$43.0M52%
System sales and rentals$23.4M28%
Other$11.1M13%
Service$5.6M7%

Related Comparisons